GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 9 Meters Biopharma Inc (OTCPK:NMTRQ) » Definitions » Net Margin %
中文

9 Meters Biopharma (9 Meters Biopharma) Net Margin % : 0.00% (As of Mar. 2023)


View and export this data going back to 2016. Start your Free Trial

What is 9 Meters Biopharma Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. 9 Meters Biopharma's Net Income for the three months ended in Mar. 2023 was $-13.87 Mil. 9 Meters Biopharma's Revenue for the three months ended in Mar. 2023 was $0.00 Mil. Therefore, 9 Meters Biopharma's net margin for the quarter that ended in Mar. 2023 was 0.00%.

The historical rank and industry rank for 9 Meters Biopharma's Net Margin % or its related term are showing as below:


NMTRQ's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -163.08
* Ranked among companies with meaningful Net Margin % only.

9 Meters Biopharma Net Margin % Historical Data

The historical data trend for 9 Meters Biopharma's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

9 Meters Biopharma Net Margin % Chart

9 Meters Biopharma Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

9 Meters Biopharma Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of 9 Meters Biopharma's Net Margin %

For the Biotechnology subindustry, 9 Meters Biopharma's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


9 Meters Biopharma's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 9 Meters Biopharma's Net Margin % distribution charts can be found below:

* The bar in red indicates where 9 Meters Biopharma's Net Margin % falls into.



9 Meters Biopharma Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

9 Meters Biopharma's Net Margin for the fiscal year that ended in Dec. 2022 is calculated as

Net Margin=Net Income (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-43.766/0
= %

9 Meters Biopharma's Net Margin for the quarter that ended in Mar. 2023 is calculated as

Net Margin=Net Income (Q: Mar. 2023 )/Revenue (Q: Mar. 2023 )
=-13.868/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


9 Meters Biopharma  (OTCPK:NMTRQ) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


9 Meters Biopharma Net Margin % Related Terms

Thank you for viewing the detailed overview of 9 Meters Biopharma's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


9 Meters Biopharma (9 Meters Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
4509 Creedmoor Road, Suite 201, Raleigh, NC, USA, 27612
9 Meters Biopharma Inc is a clinical-stage biopharmaceutical company focused on rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS), celiac disease, and three early-stage candidates for undisclosed rare diseases and/or unmet needs. Its products include NM-002, Larazotide, NM-003, and others.
Executives
Bethany Sensenig officer: Chief Financial Officer C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
John Temperato director, officer: Chief Executive Officer C/O MELINTA THERAPEUTICS,INC., 300 GEORGE STREET, SUITE 301, NEW HAVEN CT 06511
Mark A Sirgo director C/O BIODELIVERY SCIENCES INTERNATIONAL, 801 CORPORATE CENTER DRIVE -SUITE 210, RALEIGH NC 27607
Michael T. Constantino director C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Samantha Ventimiglia director C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Edward J Sitar officer: Chief Financial Officer 39 FLAMING ARROW ROAD, MAHWAH NJ 07430
Orbimed Israel Biofund Gp Limited Partnership 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 1022-4629
Yehuda Michael Rice director 155 WALNUT STREET, ENGLEWOOD NJ 07631
Nissim Darvish director, 10 percent owner C/O INNOVATE BIOPHARMACEUTICALS, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Orbimed Israel Gp Ltd. 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629
Sandeep Laumas director, officer: Executive Chairman 8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
Jay P. Madan director, officer: President 8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
Roy Proujansky director 144 PAU NEL DRIVE, LANDENBERG PA 19350
Christopher P. Prior director, officer: Chief Executive Officer 8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
June Sherie Almenoff officer: COO and Chief Medical Officer C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY 10019

9 Meters Biopharma (9 Meters Biopharma) Headlines

From GuruFocus